Skeletal Health Part 1: Overview Of Bone Health and Management In the Cancer Setting.
Cancer-induced bone disease and cancer therapy-induced bone loss are significant skeletal problems related to the treatment for urological and other cancers. Our team of specialists and nurse practitioners developed a nurse practitioner-led Bone Support Clinic for urologic cancer patients at a university hospital in London, England, United Kingdom, to address this issue. The clinic has been well-accepted, has made a positive impact on the patient journey, helps to ensure continuity of care, and highlights patients who require assessment or treatment for impending skeletal-related events in a timely fashion. This article has been divided into two parts for improved readability.
Bruce
B
Turner
Sacha
S
Ali
Lawrence
L
Drudge-Coates
Jhumur
J
Pati
Vinod
V
Nargund
Paula
P
Wells
D000970:Antineoplastic Agents / Q000009:adverse effects; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D000069448:Denosumab / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D010024:Osteoporosis / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000517:prevention & control*
D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000069448:Denosumab